Alternative Drug Delivery Approaches for the Therapy of Inflammatory Bowel Disease

Meißner, Yvette; Lamprecht, Alf

doi:10.1002/jps.21216

Cited by 72 publications

(27 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many efforts have been made for a higher specificity of drug release by designing new drug delivery devices [2,3], all marketed delivery systems still appear to be insufficiently selective [4]. This is due to the fact that the drug release mechanisms are based on physiological parameters which are not related to the inflammation and barely to its location.…”

Section: Introductionmentioning

confidence: 98%

The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis

et al. 2008

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis

et al. 2008

Self Cite

View full text Add to dashboard Cite

“…1, 2 In recent years, the incidence of UC is rapidly increasing worldwide, especially in many developing countries. 3 Although a lot of efforts have been made to find the reasons for the genesis and development of UC, its etiology still remains unclear to date.…”

Section: Introductionmentioning

confidence: 99%

Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy

Chen

et al. 2017

J. Mater. Chem. B

View full text Add to dashboard Cite

Oral drug delivery has been considered as a promising strategy for ulcerative colitis (UC) therapy. Here, an emulsion solvent evaporation technique was employed to prepare non-porous curcumin (CUR)-loaded polymeric nanoparticles (NPs) and porous CUR-loaded polymeric NPs in the absence or presence of ammonium bicarbonate. The resultant CUR-loaded NPs (non-porous NPs and porous NPs) had a desirable mean particle size of around 260 nm with a narrow size distribution, a uniform pore size distribution, slightly negative-charged surface, high encapsulation efficiency and controlled drug release capacity. In vitro experiments indicated that Raw 264.7 macrophages exhibited time-dependent accumulation profiles of NPs during the initial 2 h of co-incubation. Furthermore, we found that porous NPs inhibited the secretion of the main pro-inflammatory cytokines (TNF-α, IL-6 and IL-12) and the production of reactive oxygen species much more efficiently than non-porous NPs. Most importantly, in vivo studies demonstrated that oral administered porous NPs had a superior therapeutic efficiency in alleviating UC compared with non-porous NPs. The results collectively suggest that porous polymeric NPs can be exploited as efficient oral drug carriers for UC treatment.

show abstract

“…The earliest nanotherapeutics designed for IBD-targeted therapy are based on the physiological features that are particular to colon to trigger drug release[9]. However, physiological conditions can differ among patients and at various stages of IBD, making it very difficult to attain sufficient therapeutic efficiency.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease

Si¹,

Merlin²,

Xiao³

2016

WJG

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.

show abstract

Alternative Drug Delivery Approaches for the Therapy of Inflammatory Bowel Disease

Cited by 72 publications

References 88 publications

The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis

The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis

Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy

Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease

Contact Info

Product

Resources

About